戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rthropathy, psoriatic arthritis and juvenile spondyloarthropathy.
2 e use of ultrasound imaging in patients with spondyloarthropathy.
3 ion of disease in patients with seronegative spondyloarthropathy.
4  control of chronic uveitis in patients with spondyloarthropathy.
5 eing investigated in the various subtypes of spondyloarthropathy.
6  may be part of a systemic illness such as a spondyloarthropathy.
7 as well as specifically, in association with spondyloarthropathy.
8 re was no improvement in symptoms related to spondyloarthropathy.
9 yloarthropathies, including 80 with juvenile spondyloarthropathy.
10 d enthesitis, is a characteristic feature of spondyloarthropathy.
11 l system, including rheumatoid arthritis and spondyloarthropathies.
12 ed the association between HLA-B27 and human spondyloarthropathies.
13 ciated with a group of human diseases called spondyloarthropathies.
14 y be applicable to other HLA-B*27-associated spondyloarthropathies.
15 rthropathies (SpAs), particularly peripheral spondyloarthropathies.
16 toward ankylosing spondylitis (AS) and other spondyloarthropathies.
17 of eye disease in patients with seronegative spondyloarthropathies.
18  often effective for uveitis associated with spondyloarthropathies.
19 tations in patients affected by seronegative spondyloarthropathies.
20 has proven very successful for patients with spondyloarthropathies.
21 icularly those with rheumatoid arthritis and spondyloarthropathies.
22 lation of psoriatic arthritis with the other spondyloarthropathies.
23 hypothesis concerning the role of B27 in the spondyloarthropathies.
24 ther investigation of the role of HLA-B27 in spondyloarthropathies.
25 the classification and treatment of juvenile spondyloarthropathies.
26 e detection of sacroiliitis in children with spondyloarthropathies.
27 eviews the recent literature on the juvenile spondyloarthropathies.
28 lications for the mechanisms of synovitis in spondyloarthropathies.
29 n the HLA-B27 B pocket and susceptibility to spondyloarthropathies.
30 e of bone changes seen in some patients with spondyloarthropathies.
31 itis, juvenile rheumatoid arthritis, and the spondyloarthropathies.
32 n (Tap/Lmp), have been postulated in certain spondyloarthropathies.
33 tive in psoriasis, with promising results in spondyloarthropathies also emerging.
34 bility to ankylosing spondylitis and related spondyloarthropathies, although the underlying molecular
35 is association varies markedly among various spondyloarthropathies and among ethnic groups.
36 s strongly associated with susceptibility to spondyloarthropathies and can cause arthritis when expre
37 atory diseases such as rheumatoid arthritis, spondyloarthropathies and inflammatory bowel disease, an
38 rolling uveitis associated with seronegative spondyloarthropathies and juvenile idiopathic arthritis;
39 rs of multiple diseases including psoriasis, spondyloarthropathy and multiple sclerosis.
40 erlying process of inflammatory arthritis in spondyloarthropathy and other inflammatory arthritides.
41  disease, juvenile dermatomyositis, juvenile spondyloarthropathy and systemic vascular disease.
42 oint diseases, such as rheumatoid arthritis, spondyloarthropathies, and other arthritic joint disease
43 hritis, reactive arthritis, undifferentiated spondyloarthropathy, and arthritis associated with infla
44 able among controls and individuals with RA, spondyloarthropathy, and CPPD.
45  arthritis, systemic lupus erythematosus and spondyloarthropathy, and preclinical models suggest that
46  severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patients requiring
47 tory arthritides included in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic a
48                                              Spondyloarthropathies are a cluster of interrelated and
49                                          The spondyloarthropathies are a group of conditions which sh
50                             The seronegative spondyloarthropathies are a group of disorders sharing c
51                                          The spondyloarthropathies are a group of rheumatic diseases
52                                              Spondyloarthropathies are closely related to genetics an
53 ing recognition of the natural course of the spondyloarthropathies are leading to a more rational the
54                                     Although spondyloarthropathies are not associated with rheumatoid
55                                              Spondyloarthropathies belong to a group of rheumatic dis
56  HLA-B27 is highly associated with the human spondyloarthropathies, but the basis for this associatio
57 ssociated with the rheumatic diseases termed spondyloarthropathies, but the mechanism is not known.
58                                          The spondyloarthropathy classification criteria continue to
59 is, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Perman
60 gic research relevant to the pathogenesis of spondyloarthropathies concerns the relationship between
61 nic arthritis, including those with juvenile spondyloarthropathy, concluded that it was safe and effe
62                    In case of other types of spondyloarthropathies diagnosis is made based on presenc
63 on to the ubiquitous nature of enthesitis in spondyloarthropathies, especially adjacent to synovial j
64 both adult and juvenile disease criteria for spondyloarthropathy exist, the place of psoriatic arthri
65 tis constitutes a discreet subset within the spondyloarthropathy group, but the demarcation continues
66   Although association of HLA-B27 with human spondyloarthropathies has been known for several years,
67 ce of enthesitis as a skeletal phenomenon in spondyloarthropathies has gained further support from tr
68 , HLA-B27, which is strongly associated with spondyloarthropathy, has also been shown to stimulate IL
69                       Topics relating to the spondyloarthropathies have been reviewed recently, but t
70             The mediators of inflammation in spondyloarthropathies have begun to be elucidated.
71 diseases, including rheumatoid arthritis and spondyloarthropathies, have been critical for identifica
72 nd specific for identifying undifferentiated spondyloarthropathies in adults have been developed, and
73 uence of HIV infection on the development of spondyloarthropathies in Africa.
74    A second theme has come from the study of spondyloarthropathies in different ethnic groups and soc
75  physical activity in patients with juvenile spondyloarthropathy in remission and suggested a decline
76   This is especially relevant in the case of spondyloarthropathy in which case prevention of the nove
77                              Pathogenesis of spondyloarthropathy, in particular the part played by HL
78 s emphasized clinical characteristics of the spondyloarthropathies including reactive arthritis.
79 ophosphate deposition disease), seronegative spondyloarthropathies (including psoriatic arthritis, re
80 und in a Mexican population of patients with spondyloarthropathies, including 80 with juvenile spondy
81 nt progress in disease-modifying therapy for spondyloarthropathy, including new biologic response mod
82 e influence of HLA-B27 on the development of spondyloarthropathies is undisputed, its role in pathoge
83  to appear in swollen joints associated with spondyloarthropathy is an enthesitis (inflammation at si
84             We propose that the synovitis of spondyloarthropathy is secondary to liberation of proinf
85 ary synovial (rheumatoid-like) or entheseal (spondyloarthropathy-like) and allows differentiation of
86 on of a polyarthritis with a good prognosis (spondyloarthropathy-like), from that with a bad prognosi
87  10,484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha anta
88                                 Inflammatory spondyloarthropathies (n = 18,372; 6.6%, 95% CI 6.5%-6.7
89 ive individuals with documented RA (n = 15), spondyloarthropathy (n = 15), and calcium pyrophosphate
90                                              Spondyloarthropathies occur in genetically predisposed p
91 orders, including predominantly T helper 17-(spondyloarthropathy pattern) and T helper 2-mediated dis
92 agnoses of juvenile idiopathic arthritis and spondyloarthropathy predict reduced remission incidence;
93 uding rheumatoid arthritis, Crohn's disease, spondyloarthropathies, psoriasis and allograft rejection
94 inumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosin
95 isease, reactive arthritis, undifferentiated spondyloarthropathy, psoriatic arthritis and juvenile sp
96            Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antago
97 stions concerning classification of juvenile spondyloarthropathies remain unresolved.
98                     The taxonomy of juvenile spondyloarthropathy remains a contentious issue, and fur
99 sorders collectively termed the seronegative spondyloarthropathies (SpA) include ankylosing spondylit
100                                          The spondyloarthropathies (SpAs) are a group of interrelated
101 t common group of rheumatoid disorders, i.e. spondyloarthropathies (SpAs), particularly peripheral sp
102 usceptibility to a group of disorders termed spondyloarthropathies (SpAs).
103 rthritis and psoriasis that form part of the spondyloarthropathy spectrum.
104         The predictive value of the European Spondyloarthropathy Study Group criteria for spondyloart
105  classification criterion, from the European Spondyloarthropathy Study Group, encompasses the current
106 h bone proliferation suggests a seronegative spondyloarthropathy, such as psoriatic arthritis, reacti
107 on of IL-23 biology is a unifying feature of spondyloarthropathy, suggesting that treatments targetin
108      We have included studies on adult onset spondyloarthropathies that are particularly relevant to
109 p a spontaneous disease resembling the human spondyloarthropathies that includes arthritis and coliti
110 ive arthritis (ReA) is an HLA-B27-associated spondyloarthropathy that is triggered by diverse bacteri
111 g more like rheumatic fever and a group with spondyloarthropathy traits.
112 Spondyloarthropathy Study Group criteria for spondyloarthropathy varies with the prevalence of the di
113 of juvenile arthritis including the juvenile spondyloarthropathies was investigated and suggested a r
114 nosis with juvenile idiopathic arthritis and spondyloarthropathy were also associated with reduced re
115 systemic lupus erythematosus, as well as the spondyloarthropathies which more closely resemble the au
116 lar therapeutic challenges are raised by the spondyloarthropathies which represent a key area of unme
117 SAS discusses only the classic form of axial spondyloarthropathies, which is ankylosing spondylitis.
118 ation, published classification criteria for spondyloarthropathies, which propose standardization of
119  the connection between gut inflammation and spondyloarthropathy--which has been carefully documented
120   In arthritis of the axial skeleton, mainly spondyloarthropathies, whole-body MR imaging reveals add
121 ution to the problem of the association of a spondyloarthropathy with several

 
Page Top